Read the latest insights we've been sharing on LinkedIn

<>

March 1, 2024

Rare Disease Day 2024

by Real Endpoints

At Real Endpoints, Rare Disease Day isn't just another awareness day—it's personal. Many of us here have been directly touched by the challenges and triumphs associated with living with a rare disease, whether through personal experience or those of friends and loved ones.

LinkedIn >

February 27, 2024

PR Newswire: press release distribution, targeting, monitoring and marketing

by Real Endpoints

The team at Real Endpoints has been working tirelessly to improve RE Assist, a simple, easy-to-use AI-based platform designed to solve a critical gap in the market: providing patients with real-time information about available third-party foundation dollars for prescription meds.

LinkedIn >

February 19, 2024

Are We Valuing Prescription Drugs Appropriately?

by Real Endpoints

This new Health Affairs Forefront article explains in simple language why it's past time to update the methodology underpinning how we value - and ultimately price - drugs.

read full article >

February 19, 2024

Friday thoughts ahead of a long weekend by Real Endpoints chair Roger Longman

by Roger Longman

As Interest Rates Begin to Drop, which Biotechs Will Get an Unfair Share of New Investment?

LinkedIn >

February 12, 2024

Amazon cutting hundreds of jobs in health care units One Medical and Amazon Pharmacy

by Real Endpoints

Your semi-regular reminder: Healthcare. Is. Hard.

LinkedIn >

February 5, 2024

Let’s stipulate: the new Cell and Gene Therapy Model that CMS just released raises a lot more questions than it answers.

by Roger Longman

But for me the big point is: CMS has done something bold and novel – creating what could be a path to getting life-altering but extremely expensive therapies to people who simply wouldn’t be able to get them otherwise. Yes, the unknowns loom large. The biggest: will the counterparties – Medicaid plans and manufacturers – want to play?

LinkedIn >